中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(4): 694-699

Value of Fetuin-A， Fetuin-B， and insulin resistance index in predicting nonalcoholic fatty liver disease

DOI: 10.12449/JCH240409
  • a.

    Preventive Health Care Department, The First Affiliated Hospital of Dali University，Dali，Yunnan 671000，China

  • b.

    Department of Gastroenterology, The First Affiliated Hospital of Dali University，Dali，Yunnan 671000，China

  • c.

    Department of Geriatrics，The First Affiliated Hospital of Dali University，Dali，Yunnan 671000，China

Research funding:

Yunnan Provincial Joint Basic Research Project for Local Undergraduate Colleges and Universities (202001BA070001-103)

More Information
  • Corresponding author: LI Lihua， lilihuayncn@163.com （ORCID： 0000-0003-3987-5851）
  • Received Date: 2023-07-15
  • Accepted Date: 2023-08-04
  • Published Date: 2024-04-25
    Abstract
  •   Objective  To investigate the value of serum Fetuin-A and Fetuin-B combined with Homeostasis Model Assessment of Insulin Resistance （HOMA-IR） in predicting nonalcoholic fatty liver disease （NAFLD）.  Methods  A total of 120 patients with NAFLD who attended Department of Gastroenterology， The First Affiliated Hospital of Dali University， from June 2020 to June 2021， and 120 healthy individuals who underwent physical examination at Physical Examination Center during the same period of time were enrolled as subjects， and clinical data were collected from all subjects. The serum levels of Fetuin-A and Fetuin-B were measured. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups， and the chi-square test was used for comparison of categorical data between two groups； the multivariate Logistic regression analysis was used to assess the risk factors for NAFLD. The receiver operating characteristic （ROC） curve was plotted to evaluate the predictive efficacy of Fetuin-A and Fetuin-B combined with HOMA-IR in NAFLD patients.  Results  Compared with the healthy control group， the NAFLD group had significantly higher levels of body mass index， systolic blood pressure， diastolic blood pressure， alanine aminotransferase， aspartate aminotransferase， fasting blood glucose， fasting insulin， triglycerides， HOMA-IR， Fetuin-A， and Fetuin-B （all P<0.05）. The multivariate Logistic regression analysis showed that Fetuin-A （odds ratio ［OR］=1.010， 95% confidence interval ［CI］： 1.001‍‍‍ ‍‍‍—‍‍‍ ‍‍1.020， P<0.05）， Fetuin-B （OR=1.113， 95%CI： 1.021‍ ‍‍—‍‍ ‍1.214， P<0.05）， and HOMA-IR （OR=24.053， 95%CI： 2.624‍ ‍‍—‍‍ ‍220.470， P<0.05） were independent risk factors for NAFLD. The ROC curve analysis showed that Fetuin-A， Fetuin-B or HOMA-IR alone had an area under the ROC curve （AUC） of 0.637 （95%CI： 0.551‍ ‍—‍ ‍0.722）， 0.853 （95%CI： 0.796‍ ‍—‍ ‍0.912）， and 0.837 （95%CI： 0.763‍ ‍—‍ ‍0.912）， respectively， and Fetuin-A combined with Fetuin-B， Fetuin-A combined with HOMA-IR， and Fetuin-B combined with HOMA-IR had an AUC of 0.853 （95%CI： 0.795‍ ‍—‍ ‍0.911）， 0.843 （95%CI： 0.770‍ ‍—‍ ‍0.916）， 0.922 （95%CI： 0.877‍ ‍—‍ ‍0.967）， respectively， while the combination of these three indicators had an AUC of 0.922 （95%CI： 0.877‍ ‍—‍ ‍0.966）.  Conclusion  Fetuin-A and Fetuin-B have a certain value in predicting NAFLD， and Fetuin-B combined with HOMA-IR tends to have a higher predictive value.

     

    • FullText(HTML)
    • References(32)
  • [1]
    YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD) and nonalcoholic steatohepatitis(NASH): A systematic review[J]. Hepatology, 2023, 77( 4): 1335- 1347. DOI: 10.1097/HEP.0000000000000004.
    [2]
    ESTES C, ANSTEE QM, ARIAS-LOSTE MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69( 4): 896- 904. DOI: 10.1016/j.jhep.2018.05.036.
    [3]
    WU CM, ZHANG CY, XU HL, et al. Epidemiological research and diagnosis of nonalcoholic fatty liver disease in China[J]. China Med Herald, 2023, 20( 11): 158- 161. DOI: 10.20047/j.issn1673-7210.2023.11.36.

    吴车敏, 张从玉, 徐慧丽, 等. 我国非酒精性脂肪性肝病的流行病学研究和诊断现状分析[J]. 中国医药导报, 2023, 20( 11): 158- 161. DOI: 10.20047/j.issn1673-7210.2023.11.36.
    [4]
    SARDANA O, GOYAL R, BEDI O. Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD[J]. Inflammopharmacology, 2021, 29( 4): 1061- 1074. DOI: 10.1007/s10787-021-00837-4.
    [5]
    CHEKOL ABEBE E, TILAHUN MUCHE Z, BEHAILE T/MARIAM A, et al. Role of fetuin-A in the pathogenesis of psoriasis and its potential clinical applications[J]. Clin Cosmet Investig Dermatol, 2022, 15: 595- 607. DOI: 10.2147/CCID.S356801.
    [6]
    STEFAN N, FRITSCHE A, WEIKERT C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes[J]. Diabetes, 2008, 57( 10): 2762- 2767. DOI: 10.2337/db08-0538.
    [7]
    SONG AY, XU M, BI YF, et al. Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults[J]. PLoS One, 2011, 6( 4): e19228. DOI: 10.1371/journal.pone.0019228.
    [8]
    SUN JR, ZHANG D, XU J, et al. Circulating FABP4, nesfatin-1, and osteocalcin concentrations in women with gestational diabetes mellitus: A meta-analysis[J]. Lipids Health Dis, 2020, 19( 1): 199. DOI: 10.1186/s12944-020-01365-w.
    [9]
    XIAO Y, SHU LL, WU XP, et al. Fatty acid binding protein 4 promotes autoimmune diabetes by recruitment and activation of pancreatic islet macrophages[J]. JCI Insight, 2021, 6( 7): e141814. DOI: 10.1172/jci.insight.141814.
    [10]
    OLIVIER E, SOURY E, RUMINY P, et al. Fetuin-B, a second member of the fetuin family in mammals[J]. Biochem J, 2000, 350( Pt 2): 589- 597.
    [11]
    MUSTAFA AI, KADAH AS, FAWZY EM, et al. Serum fetuin-A: A novel potential link between post-adolescent acne and insulin resistance[J]. J Clin Aesthet Dermatol, 2022, 15( 12): 33- 37.
    [12]
    DENG WJ, GU J, ZUO LJ, et al. The level changes and influencing factors of serum fetuin-B in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease[J]. Chin J Diabetes, 2019, 27( 3): 198- 201. DOI: 10.3969/j.issn.1006-6187.2019.03.007.

    邓文娟, 谷君, 左丽娟, 等. 2型糖尿病合并非酒精性脂肪性肝病患者血清胎球蛋白B水平变化及影响因素分析[J]. 中国糖尿病杂志, 2019, 27( 3): 198- 201. DOI: 10.3969/j.issn.1006-6187.2019.03.007.
    [13]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [14]
    YOUNOSSI ZM, HENRY L, BUSH H, et al. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Clin Liver Dis, 2018, 22( 1): 1- 10. DOI: 10.1016/j.cld.2017.08.001.
    [15]
    STEFAN N, HENNIGE AM, STAIGER H, et al. Alpha2-heremans-schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans[J]. Diabetes Care, 2006, 29( 4): 853- 857. DOI: 10.2337/diacare.29.04.06.dc05-1938.
    [16]
    CHEKOL ABEBE E, TILAHUN MUCHE Z, BEHAILE T/MARIAM A, et al. The structure, biosynthesis, and biological roles of fetuin-A: A review[J]. Front Cell Dev Biol, 2022, 10: 945287. DOI: 10.3389/fcell.2022.945287.
    [17]
    LI LN, SPRANGER L, STOBÄUS N, et al. Fetuin-B, a potential link of liver-adipose tissue cross talk during diet-induced weight loss-weight maintenance[J]. Nutr Diabetes, 2021, 11( 1): 31. DOI: 10.1038/s41387-021-00174-z.
    [18]
    DI MINNO A, ZANOBINI M, MYASOEDOVA VA, et al. Could circulating fetuin A be a biomarker of aortic valve stenosis?[J]. Int J Cardiol, 2017, 249: 426- 430. DOI: 10.1016/j.ijcard.2017.05.040.
    [19]
    Low serum fetuin-a as a biomarker to predict pneumococcal necrotizing pneumonia and hemolytic uremic syndrome in children: Erratum[J]. Medicine, 2018, 97( 3): e9684. DOI: 10.1097/MD.0000000000009684.
    [20]
    ZHOU ZW, SUN MZ, JIN H, et al. Fetuin-A to adiponectin ratio is a sensitive indicator for evaluating metabolic syndrome in the elderly[J]. Lipids Health Dis, 2020, 19( 1): 61. DOI: 10.1186/s12944-020-01251-5.
    [21]
    ZHAO LL, SHANG Y, LUO QZ, et al. Decreased plasma fetuin-A level as a novel bioindicator of poor prognosis in community-acquired pneumonia: A multi-center cohort study[J]. Front Med, 2022, 9: 807536. DOI: 10.3389/fmed.2022.807536.
    [22]
    DIAO WQ, SHEN N, DU YP, et al. Fetuin-B(FETUB): A plasma biomarker candidate related to the severity of lung function in COPD[J]. Sci Rep, 2016, 6: 30045. DOI: 10.1038/srep30045.
    [23]
    YURTCU N, ORAL S, CELIK S, et al. Predıctıve value of pregnancy of follıcular fluıd fetuın-A and-B levels ın infertıle women after intra-cytoplasmic sperm injection[J]. J Obstet And Gynaecol, 2022, 48( 1): 178- 187. DOI: 10.1111/jog.15070.
    [24]
    LIU SS, XIAO JH, ZHAO ZZ, et al. Systematic review and meta-analysis of circulating fetuin-a levels in nonalcoholic fatty liver disease[J]. J Clin Transl Hepatol, 2021, 9( 1): 3- 14. DOI: 10.14218/JCTH.2020.00081.
    [25]
    LU CW, LEE YC, CHIANG CH, et al. Independent dose-response associations between fetuin-A and lean nonalcoholic fatty liver disease[J]. Nutrients, 2021, 13( 9): 2928. DOI: 10.3390/nu13092928.
    [26]
    BALLESTRI S, MESCHIARI E, BALDELLI E, et al. Relationship of serum fetuin-a levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography[J]. Metab Syndr Relat Disord, 2013, 11( 4): 289- 295. DOI: 10.1089/met.2012.0149.
    [27]
    IX JH, SHARMA K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: The roles of fetuin-A, adiponectin, and AMPK[J]. J Am Soc Nephrol, 2010, 21( 3): 406- 412. DOI: 10.1681/ASN.2009080820.
    [28]
    LANTHIER N, LEBRUN V, MOLENDI-COSTE O, et al. Liver fetuin-A at initiation of insulin resistance[J]. Metabolites, 2022, 12( 11): 1023. DOI: 10.3390/metabo12111023.
    [29]
    PETER A, KOVAROVA M, STAIGER H, et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans[J]. Am J Physiol Endocrinol Metab, 2018, 314( 3): E266- E273. DOI: 10.1152/ajpendo.00262.2017.
    [30]
    CHOI JW, LIU H, MUKHERJEE R, et al. Downregulation of fetuin-B and zinc-α2-glycoprotein is linked to impaired fatty acid metabolism in liver cells[J]. Cell Physiol Biochem, 2012, 30( 2): 295- 306. DOI: 10.1159/000339065.
    [31]
    DABROWSKA AM, TARACH JS, WOJTYSIAK-DUMA B, et al. Fetuin-A(AHSG) and its usefulness in clinical practice. Review of the literature[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2015, 159( 3): 352- 359. DOI: 10.5507/bp.2015.018.
    [32]
    ZHAO CL, SHANG DF, ZHOU C, et al. Mechanism of lipid metabolism mediated by hepatokines and adipokines in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 1): 168- 174. DOI: 10.3969/j.issn.1001-5256.2023.01.026.

    赵晨露, 尚东方, 周铖, 等. 肝因子和脂肪因子介导的脂代谢在非酒精性脂肪性肝病中的作用机制[J]. 临床肝胆病杂志, 2023, 39( 1): 168- 174. DOI: 10.3969/j.issn.1001-5256.2023.01.026.
    • Relative Articles

  • Relative Articles

    [1]Heng ZHU, Weizong KONG, Guiqun HUANG, Yu BAI, Yingchun WANG. Influence of histone deacetylase 1 on insulin resistance in a cell model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(9): 2010-2015. doi: 10.3969/j.issn.1001-5256.2022.09.013
    [2]Juan WANG, Yingchun WANG, Chunyu WANG. Association between monocyte-to-high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(5): 1137-1141. doi: 10.3969/j.issn.1001-5256.2021.05.031
    [3]Peiyu ZHENG, Xiuqin AN, Jinchun LIU. Role of angiopoietin-like proteins in the development of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2680-2683. doi: 10.3969/j.issn.1001-5256.2021.11.042
    [4]A RuHan, Jia HaiYan, Ding YanHua, Niu JunQi. Research advances in nonalcoholic fatty liver disease in lean individuals[J]. Journal of Clinical Hepatology, 2020, 36(5): 1154-1159. doi: 10.3969/j.issn.1001-5256.2020.05.046
    [5]ZHANG SuYan, XIA EnRui, ZHOU QingLi, ZHANG ShunZhen. Effect of Quzhi Ruangan decoction on the mRNA and protein expression of organic anion transporting polypeptide 2B1 in the small intestine of rats with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2484-2488. doi: 10.3969/j.issn.1001-5256.2020.11.017
    [6]Yue HaiYan, Liu ShouSheng, Wang Cong, Gu JiuLian, Xin YongNing, Xuan ShiYing. Association between single nucleotide polymorphism of low-density lipoprotein receptor and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(9): 1929-1935. doi: 10.3969/j.issn.1001-5256.2018.09.021
    [7]Yang Shuai, He SongQing. Role of silent information regulator 1 in development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(3): 649-652. doi: 10.3969/j.issn.1001-5256.2018.03.047
    [8]Dou AiHua, Hui Wei, Liu Mei, Wei LinLin, Zhao Juan, Ma ChunHua, Zheng XiaoQin, Xiong Fang, Yang Xue, Zhang Mei, Xu Bin. Association between rs2943650 mutation and insulin resistance in patients with chronic liver disease and type 2 diabetes mellitus[J]. Journal of Clinical Hepatology, 2018, 34(11): 2379-2382. doi: 10.3969/j.issn.1001-5256.2018.11.022
    [9]Liu DaJi, Chen QingFeng. Pathogenesis of insulin resistance and its impact on antiviral therapy in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2017, 33(6): 1152-1155. doi: 10.3969/j.issn.1001-5256.2017.06.029
    [10]Ding ZhiYong, Bu Le, Lu HongYan, Rao ZhengXuan. Correlation of liver fat content with serum vitamin A level and insulin resistance in patients with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2361-2365. doi: 10.3969/j.issn.1001-5256.2017.12.021
    [11]Zhang QiuNan, Xiao Ying, Miao RuiXin, Zhang YaQing, Zhu Ying. Changes in intestinal flora in nonalcoholic fatty liver disease: their correlation with insulin resistance index,tumor necrosis factor- α,and interleukin- 6[J]. Journal of Clinical Hepatology, 2015, 31(7): 1078-1081. doi: 10.3969/j.issn.1001-5256.2015.07.019
    [12]Guo YinYan, Li Peng. A study on the role of serum Retinol Binding Protein 4 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(4): 279-280+301.
    [13]Ma LiNa, Feng Ming, Zhou YingZhi, Ma Jia, Hao Peng. The relationship between nonalcoholic fatty liver disease and insulin resistance[J]. Journal of Clinical Hepatology, 2010, 26(2): 173-174+177.
    [14]Yu XiaoHu, Zhu JinShui, Gu GuoMei, Shi JianPing. Clinical effect of oxymatrine combined with metformin on insulin resistance and serum TNF-α in patients with non-alcoholic fatty liver[J]. Journal of Clinical Hepatology, 2007, 23(3): 195-196.
    [15]Zhang FenMing, Gao SuQin, Kong DeZhi. Relationship between nonalcoholic fatty liver disease and insulin resistance in hypertensive patients[J]. Journal of Clinical Hepatology, 2007, 23(4): 277-279.
    [16]Li YuQin, Po YunFeng, Chen ZhaoJie, Ding BaiJing, Tang TongYu, Wang Dan, Gao YanHang, Jin JingLan. Relationship between the levels of serum leptin and insulin resistance in patients with fatty liver[J]. Journal of Clinical Hepatology, 2007, 23(5): 360-361.
    [17]Liang Bing, Chen Xi, Liu ShuangYan, Wang YiGe, An QiuHong. The relationship between non-alcoholic fatty liver disease and insulin resistance[J]. Journal of Clinical Hepatology, 2006, 22(3): 213-214.
    [19]Huang JiLiang, Wu Fang, Zhang XinRan, Wang DongHua, Zhao RuiZhi. Relationship between tumor necrosis factor-α and lnsulin resistance in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2002, 18(3): 166-167.
    [20]Ma YingJie, Fang LiFeng, Feng SuPing, Jia KeLi, Fu ZhenLie. Obesity and insulin resistance in nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2002, 18(4): 241-242.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 22.1 %FULLTEXT: 22.1 %META: 69.6 %META: 69.6 %PDF: 8.4 %PDF: 8.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 11.5 %其他: 11.5 %其他: 0.2 %其他: 0.2 %China: 0.3 %China: 0.3 %Russian Federation: 0.2 %Russian Federation: 0.2 %Tiruchi: 0.2 %Tiruchi: 0.2 %上海: 2.5 %上海: 2.5 %东莞: 0.2 %东莞: 0.2 %伊利诺伊州: 0.2 %伊利诺伊州: 0.2 %佛山: 0.3 %佛山: 0.3 %北京: 4.1 %北京: 4.1 %南京: 0.5 %南京: 0.5 %南宁: 0.2 %南宁: 0.2 %南昌: 0.2 %南昌: 0.2 %卡纳塔克: 0.3 %卡纳塔克: 0.3 %厦门: 0.2 %厦门: 0.2 %古尔冈: 0.2 %古尔冈: 0.2 %合肥: 0.5 %合肥: 0.5 %吉林: 0.2 %吉林: 0.2 %周口: 0.3 %周口: 0.3 %咸阳: 0.2 %咸阳: 0.2 %哥伦布: 0.2 %哥伦布: 0.2 %大理: 0.3 %大理: 0.3 %娄底: 0.2 %娄底: 0.2 %孟买: 0.2 %孟买: 0.2 %安康: 0.2 %安康: 0.2 %宣城: 0.2 %宣城: 0.2 %常州: 0.2 %常州: 0.2 %常德: 0.3 %常德: 0.3 %广州: 0.9 %广州: 0.9 %廊坊: 0.2 %廊坊: 0.2 %张家口: 2.5 %张家口: 2.5 %徐州: 0.5 %徐州: 0.5 %得梅因: 0.2 %得梅因: 0.2 %德黑兰: 0.3 %德黑兰: 0.3 %成都: 0.5 %成都: 0.5 %新德里: 0.3 %新德里: 0.3 %新泽西州: 0.3 %新泽西州: 0.3 %昆明: 1.6 %昆明: 1.6 %曲靖: 0.2 %曲靖: 0.2 %杭州: 0.8 %杭州: 0.8 %格兰特县: 0.2 %格兰特县: 0.2 %梅州: 0.3 %梅州: 0.3 %武汉: 0.2 %武汉: 0.2 %毕节: 0.5 %毕节: 0.5 %沈阳: 0.6 %沈阳: 0.6 %海口: 0.2 %海口: 0.2 %海得拉巴: 0.5 %海得拉巴: 0.5 %深圳: 0.2 %深圳: 0.2 %湘潭: 0.2 %湘潭: 0.2 %班加罗尔: 0.2 %班加罗尔: 0.2 %石家庄: 0.2 %石家庄: 0.2 %福州: 0.2 %福州: 0.2 %科泽科德: 0.3 %科泽科德: 0.3 %芒廷维尤: 23.2 %芒廷维尤: 23.2 %芝加哥: 2.7 %芝加哥: 2.7 %苏州: 0.6 %苏州: 0.6 %莫斯科: 2.2 %莫斯科: 2.2 %西宁: 12.5 %西宁: 12.5 %西安: 0.5 %西安: 0.5 %西雅图: 0.2 %西雅图: 0.2 %诺沃克: 0.3 %诺沃克: 0.3 %赣州: 0.2 %赣州: 0.2 %运城: 1.3 %运城: 1.3 %遵义: 0.2 %遵义: 0.2 %郑州: 0.8 %郑州: 0.8 %重庆: 0.5 %重庆: 0.5 %镇江: 0.2 %镇江: 0.2 %长春: 16.2 %长春: 16.2 %长沙: 0.9 %长沙: 0.9 %长治: 1.3 %长治: 1.3 %青岛: 0.5 %青岛: 0.5 %香港: 0.2 %香港: 0.2 %黔南: 0.5 %黔南: 0.5 %其他其他ChinaRussian FederationTiruchi上海东莞伊利诺伊州佛山北京南京南宁南昌卡纳塔克厦门古尔冈合肥吉林周口咸阳哥伦布大理娄底孟买安康宣城常州常德广州廊坊张家口徐州得梅因德黑兰成都新德里新泽西州昆明曲靖杭州格兰特县梅州武汉毕节沈阳海口海得拉巴深圳湘潭班加罗尔石家庄福州科泽科德芒廷维尤芝加哥苏州莫斯科西宁西安西雅图诺沃克赣州运城遵义郑州重庆镇江长春长沙长治青岛香港黔南

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (440) PDF downloads(53) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2740]YesterdayPV[5247]TodayIP[2291]TodayPV[4068]Online[79]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return